Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLN | Q9BYT8 | 1/20 | 0.60 |
| ▸ | MASP2 | O00187 | 3/20 | 0.49 |
| ▸ | TPH1 | P17752 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | FCER2 | P06734 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154431 | 0.87 | MASP2 (0.56) | NLNMASP2NAMPTHDAC1CTSC | |
| SCHEMBL5556817 | 0.84 | NLN (0.62) | NLNTPH1DPP4METAP2METAP1 | |
| SCHEMBL3157855 | 0.83 | MASP2 (0.53) | NLNMASP2TPH1NAMPTDPP4 | |
| SCHEMBL3154058 | 0.83 | MASP2 (0.47) | NLNMASP2NAMPTHDAC1 | |
| SCHEMBL3144724 | 0.83 | MASP2 (0.46) | MASP2NAMPT | |
| SCHEMBL3149501 | 0.83 | ROCK2 (0.48) | NLNMASP2NAMPTHDAC1 | |
| SCHEMBL3141278 | 0.83 | MASP2 (0.51) | NLNMASP2NAMPTHDAC1 | |
| SCHEMBL3146169 | 0.83 | MASP2 (0.48) | NLNMASP2NAMPTOPRD1 | |
| SCHEMBL1901471 | 0.82 | PDPK1 (0.47) | NLNMASP2NAMPTHDAC1 | |
| SCHEMBL1901467 | 0.82 | PDPK1 (0.47) | NLNMASP2NAMPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | NLN 1402/4885MASP2 3039/4885TPH1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.